Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 9, Number 8—August 2003

Dispatch

NmcA Carbapenem-hydrolyzing Enzyme in Enterobacter cloacae in North America1

Sudha Pottumarthy*, Ellen Smith Moland†, Stefan Juretschko*, Susan R. Swanzy*, Kenneth S. Thomson†, and Thomas R. Fritsche*Comments to Author 
Author affiliations: *University of Washington School of Medicine, Seattle, Washington, USA; †Creighton University Medical Center, Omaha, Nebraska, USA

Main Article

Figure 2

Effect of addition of clavulanic acid (10 μL of 1,000 μg/mL) to the zones of inhibition of the three carbapenem disks. Top row (left to right): imipenem, meropenem, and ertapenem disks without clavulanic acid. Bottom row (left to right): imipenem, meropenem, and ertapenem disks with clavulanic acid.

Figure 2. Effect of addition of clavulanic acid (10 μL of 1,000 μg/mL) to the zones of inhibition of the three carbapenem disks. Top row (left to right): imipenem, meropenem, and ertapenem disks without clavulanic acid. Bottom row (left to right): imipenem, meropenem, and ertapenem disks with clavulanic acid.

Main Article

1This work was presented in part at the 13th Annual European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, Scotland, 2003.

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO